Investigating how unique antibody sequences may contribute to autoimmune diseases.
Divergence of V-region sequences from the human proteome as a factor in autoimmune diseases and the immunogenicity of therapeutic antibodies.
This study is looking at special types of antibodies in people with autoimmune diseases and healthy individuals to see how they might affect the immune system, helping us learn more about these conditions and how to better understand them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10991364 on NIH RePORTER |
What this research studies
This research explores the role of rare antibody sequences in autoimmune diseases by analyzing millions of antibody sequences from both healthy individuals and those with immune-mediated disorders. Using advanced data from curated databases, the study aims to identify specific sequences that may trigger immune responses in patients. By examining these unique sequences, researchers hope to better understand their potential immunogenicity and how they relate to autoimmune conditions. This large-scale analysis leverages decades of research to uncover new insights into the immune system's behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with autoimmune diseases who may have unique antibody profiles.
Not a fit: Patients without autoimmune conditions or those who do not produce antibodies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for autoimmune diseases.
How similar studies have performed: Previous research has shown promise in understanding antibody sequences and their roles in immune responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Schroeder, Harry William — University of Alabama at Birmingham
- Study coordinator: Schroeder, Harry William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.